Elevated levels of CYP2E1 have been largely attributed to the pathogenesis of liver disease in patients with nonalcoholic steatohepatitis (NASH) [3-7]. This evidence concerns the gene CYP2E1 and metabolic dysfunction-associated steatohepatitis.